Jeffrey Jay and David Kroin‘s Great Point Partners recently filed a Form 13G with the Securities and Exchange Commission in which it reported a significant increase to its stake in Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX). The fund’s position now consists of 2.77 million common shares of the company, which amass 7.57% of its outstanding stock. The fund held just 274,756 Foamix shares on June 30, as per its latest 13F filing.
As its name suggests, Foamix Pharmaceuticals is a clinical-stage pharmaceutical company that mainly works on producing minocycline foam for various skin problems. Recently, the company disclosed positive results from a phase 2 trial evaluating FMX-103 Topical Minocycline Foam for papulopustular rosacea. Over the past 12 months, the company’s stock has gained 34.5%. In its financial report for the second quarter of 2016, Foamix Pharmaceuticals reported a loss per share of $0.27 and revenue of $752,000, compared to a loss per share of $0.18 and revenue of $109,000 for the same period of the previous year.
Out of 749 smart money managers tracked by Insider Monkey which filed 13Fs for the June quarter, 17 were long Foamix Pharmaceuticals (NASDAQ:FOMX) at the end of June, up by five from the end of March. Bullish investors contained Julian Baker and Felix Baker’s Baker Bros. Advisors, which held a position valued at $14.24 million, James E. Flynn’s Deerfield Management, with a position worth $8.14 million, James A. Silverman’s Opaleye Management, Richard Driehaus’ Driehaus Capital, and Anand Parekh’s Alyeska Investment Group.
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Great Point Partners | 0 | 2,769,425 | 0 | 2,769,425 | 2,769,425 | 7.57% |
| Dr. Jeffrey R. Jay, M.D | 0 | 2,769,425 | 0 | 2,769,425 | 2,769,425 | 7.57% |
| Mr. David Kroin | 0 | 2,769,425 | 0 | 2,769,425 | 2,769,425 | 7.57% |
Follow Jeffrey Jay And David Kroin's Great Point Partners
Page 1 of 10 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 13G
Under the Securities Exchange Act of
1934
(Amendment No. )*
Foamix Pharmaceuticals Ltd.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
M46135105
(CUSIP Number)
September 28, 2016
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| o | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
*The remainder of this
cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
Persons who respond to the collection of
information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Page 2 of 10 – SEC Filing
| CUSIP No. M46135105 | 13G | Page 2 of 9 Pages |
| 1. | NAMES OF REPORTING PERSONS Great Point Partners, LLC I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES 37-1475292 | |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | |
| (a) | o | |
| (b) | o | |
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION USA | |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER | |
| 0 | |||
| 6. | SHARED VOTING POWER | ||
| 2,769,425 | |||
| 7. | SOLE DISPOSITIVE POWER | ||
| 0 | |||
| 8. | SHARED DISPOSITIVE POWER | ||
| 2,769,425 |
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING 2,769,425 | |
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) | o |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.57%1 | |
| 12. | TYPE OF REPORTING PERSON (See Instructions) IA | |
| 1 | Based on a total of 36,599,397 shares outstanding, as reported in the Issuer’s Form 424B5 Prospectus filed with the SEC on September 27, 2016. |
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Page 3 of 10 – SEC Filing
| CUSIP No. M46135105 | 13G | Page 3 of 9 Pages |
| 1. | NAMES OF REPORTING PERSONS Dr. Jeffrey R. Jay, M.D. I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): | |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | |
| (a) | o | |
| (b) | o | |
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION USA | |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER | |
| 0 | |||
| 6. | SHARED VOTING POWER | ||
| 2,769,425 | |||
| 7. | SOLE DISPOSITIVE POWER | ||
| 0 | |||
| 8. | SHARED DISPOSITIVE POWER | ||
| 2,769,425 | |||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING | |
| 2,769,425 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) | o |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |
| 7.57%1 | ||
| 12. | TYPE OF REPORTING PERSON (See Instructions) | |
| IN | ||
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Page 4 of 10 – SEC Filing
| CUSIP No. M46135105 | 13G | Page 4 of 9 Pages |
| 1. | NAMES OF REPORTING PERSONS | |
| Mr. David Kroin | ||
| I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY): | ||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | |
| (a) | o | |
| (b) | o | |
| 3. | SEC USE ONLY | |
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION USA | |
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER | |
| 0 | |||
| 6. | SHARED VOTING POWER | ||
| 2,769,425 | |||
| 7. | SOLE DISPOSITIVE POWER | ||
| 0 | |||
| 8. | SHARED DISPOSITIVE POWER | ||
| 2,769,425 |
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |
| 2,769,425 | ||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) | o |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | |
| 7.57%1 | ||
| 12. | TYPE OF REPORTING PERSON (See Instructions) | |
| IN |
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Page 5 of 10 – SEC Filing
| CUSIP No. M46135105 | 13G | Page 5 of 9 Pages |
| Item 1. | ||
| (a) | Name of Issuer | |
| Foamix Pharmaceuticals Ltd. | ||
| (b) | Address of Issuer’s Principal Executive Offices | |
| 2 Holzman St., Weizmann Science Park, Rehovot L3 76704, Israel | ||
| Item 2. | ||
| (a) | Name of Person Filing | |
| Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Mr. David Kroin | ||
| The Reporting Persons have entered into a Joint Filing Agreement, dated October 11, 2016, a copy of which is filed with this Schedule 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act. | ||
| (b) | Address of Principal Business Office, or if none, Residence | |
| The address of the principal business office of each of the Reporting Persons is | ||
| 165 Mason Street, 3rd Floor | ||
| Greenwich, CT 06830 | ||
| (c) | Citizenship | |
| Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Mr. David Kroin is a citizen of the United States. | ||
| (d) | Title of Class of Securities | |
| Common Stock | ||
| (e) | CUSIP Number | |
| M46135105 | ||
| Item 3. | If this statement is filed pursuant to §240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: | ||
| Not Applicable. | |||
| (a) | o | Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o) | |
| (b) | o | Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). | |
| (c) | o | Insurance company as defined in Section 3(a)(19) of the Act (15. U.S.C. 78c). | |
| (d) | o | Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). | |
| (e) | o | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E). | |
| (f) | o | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F). | |
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Page 6 of 10 – SEC Filing
| CUSIP No. M46135105 | 13G | Page 6 of 9 Pages |
| (g) | o | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G). | |
| (h) | o | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813). | |
| (i) | o | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3). | |
| (j) | o | Group, in accordance with §240.13d-1(b)(1)(ii)(J). | |
| Item 4. | Ownership |
| Biomedical Value Fund, L.P. (“BVF”) is the record owner of 727,127 shares of Common Stock (the “BVF Shares”). Great Point Partners, LLC (“Great Point”) is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. (“Dr. Jay”), as senior managing member of Great Point, and Mr. David Kroin (“Mr. Kroin”), as special managing member of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares. | |
| Biomedical Offshore Value Fund, Ltd. (“BOVF”) is the record owner of 1,047,995 shares of Common Stock (the “BOVF Shares”). Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares. | |
| GEF-SMA, LP (“GEF-SMA”) is the record owner of 812,519 shares of Common Stock (the “GEF-SMA Shares”). Great Point is the investment manager of GEF-SMA, and by virtue of such status may be deemed to be the beneficial owner of the GEF-SMA Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the GEF-SMA Shares, and therefore may be deemed to be the beneficial owner of the GEF-SMA Shares. | |
| Class D Series of GEF-PS, L.P. (“GEF-PS”) is the record owner of 181,784 shares of Common Stock (the “GEF-PS Shares”). Great Point is the investment manager of GEF-PS and by virtue of such status may be deemed to be the beneficial owner of the GEF-PS Shares. Each of Dr. Jay, as senior managing member of Great Point, and Mr. Kroin, as special managing member of Great Point, has voting and investment power with respect to the GEF-PS Shares, and therefore may be deemed to be the beneficial owner of the GEF-PS Shares. | |
| Notwithstanding the above, Great Point, Dr. Jay and Mr. Kroin disclaim beneficial ownership of the BVF Shares, the BOVF Shares, the GEF-SMA Shares and the GEF-PS Shares described above, except to the extent of their respective pecuniary interests. | |
| Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. | |
| 1. | Great Point Partners, LLC | ||
| (a) | Amount beneficially owned: 2,769,425 | ||
| (b) | Percent of class: 7.57%1 | ||
| (c) | Number of shares as to which the person has: | ||
| (i) | Sole power to vote or to direct the vote: 0 | ||
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Page 7 of 10 – SEC Filing
| CUSIP No. M46135105 | 13G | Page 7 of 9 Pages |
| (ii) | Shared power to vote or to direct the vote: 2,769,425 | |||
| (iii) | Sole power to dispose or to direct the disposition of: 0 | |||
| (iv) | Shared power to dispose or to direct the disposition of: 2,769,425 | |||
| 2. | Dr. Jeffrey R. Jay, M.D. | |
| (a) | Amount beneficially owned: 2,769,425 | |
| (b) | Percent of class: 7.57%1 | |
| (c) | Number of shares as to which the person has: | |
| (i) | Sole power to vote or to direct the vote: 0 | |
| (ii) | Shared power to vote or to direct the vote: 2,769,425 | |
| (iii) | Sole power to dispose or to direct the disposition of: 0 | |
| (iv) | Shared power to dispose or to direct the disposition of: 2,769,425 | |
| 3. | Mr. David Kroin | |
| (a) | Amount beneficially owned: 2,769,425 | |
| (b) | Percent of class: 7.57%1 | |
| (c) | Number of shares as to which the person has: | |
| (i) | Sole power to vote or to direct the vote: 0 | |
| (ii) | Shared power to vote or to direct the vote: 2,769,425 | |
| (iii) | Sole power to dispose or to direct the disposition of: 0 | |
| (iv) | Shared power to dispose or to direct the disposition of: 2,769,425 | |
| Item 5. | Ownership of Five Percent or Less of a Class |
If this statement is
being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of
more than five percent of the class of securities, check the following [ ].
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person: |
| See Item 4. | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company |
| Not Applicable. | |
| Item 8. | Identification and Classification of Members of the Group |
| Not Applicable. |
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Page 8 of 10 – SEC Filing
| CUSIP No. M46135105 | 13G | Page 8 of 9 Pages |
| Item 9. | Notice of Dissolution of Group |
| Not Applicable. | |
| Item 10. | Certification |
By signing below I certify
that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not
held in connection with or as participant in any transaction having that purpose or effect.
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Page 9 of 10 – SEC Filing
| CUSIP No. M46135105 | 13G | Page 9 of 9 Pages |
SIGNATURE
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: October 11, 2016
| GREAT POINT PARTNERS, LLC | |||
| By: | /s/ Dr. Jeffrey R. Jay, M.D. | ||
| Dr. Jeffrey R. Jay, M.D., | |||
| as senior managing member | |||
| /s/ Dr. Jeffrey R. Jay, M.D. | |||
| DR. JEFFREY R. JAY, M.D. | |||
| /s/ Mr. David Kroin | |||
| MR. DAVID KROIN | |||
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Follow Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)
Page 10 of 10 – SEC Filing
Exhibit A
AGREEMENT REGARDING THE JOINT FILING
OF SCHEDULE 13G
The undersigned hereby agree as follows:
(i) Each
of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf
of each of them; and
(ii) Each
of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy
of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of
the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information
is inaccurate.
Date: October 11, 2016
| GREAT POINT PARTNERS, LLC | |||
| By: | /s/ Dr. Jeffrey R. Jay, M.D. | ||
| Dr. Jeffrey R. Jay, M.D., | |||
| as senior managing member | |||
| /s/ Dr. Jeffrey R. Jay, M.D. | |||
| DR. JEFFREY R. JAY, M.D. | |||
| /s/ Mr. David Kroin | |||
| MR. DAVID KROIN | |||
